Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Newcastle disease and avian influenza (H9 subtype) bivalent inactivated vaccine
- Development stage
- Unknown
- Lead developer
- Shaanxi Youbang Biopharma Technology
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a veterinary bivalent inactivated vaccine developed by Youbang Pharmaceutical for the prevention of Newcastle disease and H9 subtype avian influenza in poultry. The vaccine is composed of inactivated Newcastle disease virus (NDV) and H9 subtype avian influenza virus (AIV). Upon administration, it stimulates the host's immune system to produce specific neutralizing antibodies against both NDV and the H9 subtype of AIV, providing protective immunity and reducing the clinical impact and viral shedding associated with these infections in chickens. It is specifically designed for the poultry industry to manage two of the most significant respiratory and systemic viral threats.
- Other names
- 鸡新城疫、禽流感(H9亚型)二联灭活疫苗Newcastle disease + H9 AI bivalent inactivated vaccineNewcastle disease virus (NDV) and Avian influenza virus (H9 subtype) inactivated vaccine
Beyond the preview
Go deeper on Newcastle disease and avian influenza (H9 subtype) bivalent inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newcastle disease and avian influenza (H9 subtype) bivalent inactivated vaccine.